Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

PHASE1CompletedINTERVENTIONAL

Enrollment

477

Participants

Timeline

Start Date

February 17, 2014

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions

Solid Tumor

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02054806 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | Biotech Hunter | Biotech Hunter